Search

Ramipril

Ramiprilat is a potent, competitive inhibitor of ACE, the enzyme responsible for the conversion of angiotensin I (ATI) to angiotensin II (ATII).

Levocetirizine

[L7694] Levocetirizine has greater affinity for the histamine H₁ receptor than cetirizine.[L7694] Levocetirizine was granted FDA approval in 1995.[L7694]

Thiram

Thiram is mainly used as a fungicide for plants and treatment for seeds, however, this use is being investigated for safety in many markets including Canada [L5425].

Atacicept

[L63797] The US FDA granted accelerated approval to atacicept-vymj on July 7, 2026, to reduce proteinuria in adults with primary IgA nephropathy at risk for disease progression.

Ziprasidone

[A190525] Luckily, several treatment options for psychotic disorders have been introduced to market since the realization of chlorpromazine's antipsychotic properties in 1952.

Bexagliflozin

[A256423,L44758] In January 2023, bexagliflozin was approved by the FDA for the treatment of adults with type 2 diabetes. … [A256413] SGLT2 is responsible for 60% to 90% of renal glucose re-uptake, and unlike other isoforms such as SGLT1, SGLT2 is mainly expressed in the kidney.

Albumin Aggregated

Albumin aggregated is an ingredient in the DRAXIMAGE MAA kit for the preparation of technetium tc99m albumin aggregated injection. … [L12816] This imaging agent is used to assess lung perfusion and for the evaluation of peritoneovenous (LeVeen) shunt patency.

Venetoclax

Previously, this drug was indicated only for patients with 17p gene deletion [F2130]. … A new indication was approved in 2018 for the treatment patients with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL), with or without 17p deletion, who have received at least one

Sodium phosphate, monobasic, unspecified form

Arimoclomol

[L51384] Arimoclomol was approved by the FDA on September 20, 2024, making it the first treatment for Niemann-Pick disease, type C (NPC).